Drug Name: Tofidence

Active Ingredient:  tocilizumab-baviIndications: Tofidence is an interleukin-6 (IL-6) receptor antagonist that targets specific inflammatory proteins to suppress the immune system. Tofidence is approved for rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis ages 2 and older, and systemic juvenile idiopathic arthritis ages 2 and older.

Approval Date: September 29, 2023

Company: Biogen Inc.

More:  https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-biosimilar-actemra-treat-adult-and-pediatric-arthritis